Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Sundise to implement Medidata Rave as its EDC and CDM solution

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Traditional Chinese Medicine company Sundise will implement Medidata Rave as its electronic data capture and clinical data management solution. Selected for its ability to offer a broad global reach with local in-country support, Medidata will work with Sundise to conduct its first U.S. trial for its TCM treatment for liver fibrosis and will play a key role in supporting the company's strategy to launch in the U.S.

11 Jun 2010

NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.

11 Jun 2010

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.

11 Jun 2010

Cellular response plays a key role in wound healing

Researchers from the University of Illinois at Chicago have discovered that an unexpected cellular response plays an important role in breaking down and inhibiting the formation of excess scar tissue in wound healing.

11 Jun 2010

Purdue University researchers develop potential new tool for medical diagnostics, testing food

Researchers at Purdue University have developed a potential new tool for medical diagnostics, testing food and water for contamination, and crime-scene forensics.

9 Jun 2010

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Some species of bacteria perform an amazing reproductive feat. When the single-celled organism splits in two, the daughter cell - the swarmer - inherits a propeller to swim freely. The mother cell builds a stalk to cling to surfaces.

4 Jun 2010

Study sheds light on how IMT improves performance in endurance sports

An Indiana University study found that strengthening inspiratory muscles by performing daily breathing exercises for six weeks significantly reduced the amount of oxygen these same breathing muscles required during exercise, possibly making more oxygen available for other muscles.

4 Jun 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

Report ranks best children's hospitals

U.S. News & World Report reports on the nation's best children's hospitals: "Out of all of the roughly 5,000 U.S. hospitals, only about 1 in 30 has deep expertise in caring for children with serious problems. For youngsters who need that quality of care, the Best Children's Hospitals rankings showcase the medical centers that see kids every day who have cancer, cystic fibrosis, defective hearts, and countless other life-threatening or rare conditions beyond the capabilities of most hospitals, even those with sizable pediatric departments.

4 Jun 2010

California examines 'never events' at hospitals; La. seeks funding for primary care clinics; Texas trims children's health program

San Francisco Chronicle: "Drill bits, screws, sponges, clamps, needles, catheters, electrodes. These are some of the things accidentally left inside patients after surgery at California hospitals.

3 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

DARA BioSciences, Inc. today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement as set forth in NASDAQ Listing Rule 5550(a)(2). On May 26, 2010, the Company's closing bid price was $3.58 per share, the tenth consecutive day it had been above $1 per share.

2 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

GenMark Diagnostics prices initial public offering

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, announced today that its initial public offering of 4,600,000 shares of its common stock has been priced at $6.00 per share. The shares are expected to begin trading today on the NASDAQ Global Market under the ticker symbol "GNMK." In addition, GenMark has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares to cover over-allotments, if any.

29 May 2010

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

Researchers at the UCLA Medical Center found that antiviral therapy during compensated cirrhosis, when compared with all other strategies, is the most cost-effective approach to treating patients with advanced liver disease due to hepatitis C infection. Full details appear in the June issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 May 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

28 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Fibrosis News and Research

Further Reading

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Sundise to implement Medidata Rave as its EDC and CDM solution

NeoPharm first-quarter net loss decreases to $1.4 million

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Cellular response plays a key role in wound healing

Purdue University researchers develop potential new tool for medical diagnostics, testing food

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Study sheds light on how IMT improves performance in endurance sports

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

Report ranks best children's hospitals

California examines 'never events' at hospitals; La. seeks funding for primary care clinics; Texas trims children's health program

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

Centocor Ortho Biotech acquires RespiVert

Major response to preoperative therapy increases survival in pancreatic cancer patients

GenMark Diagnostics prices initial public offering

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News